/smstreet/media/agency_attachments/3LWGA69AjH55EG7xRGSA.png)
/smstreet/media/member_avatars/2024-08-02t124107562z-smestreet-logo-transperant.png ){kind=logo}
Follow UsSyngene International Limited today announced its second quarter results. The Company posted quarterly total revenue of Rs. 533 Cr compared to Rs 485 Cr in the corresponding quarter of last year. EBITDA for the quarter was up 6% to Rs. 169 Cr while PAT was up 2% to Rs. 84 Cr.
Commenting on the results, Mr. Jonathan Hunt, Managing Director and Chief Executive Officer - Syngene International Limited, said: “The second quarter saw a positive return to growth following a muted first quarter that was impacted by COVID-19, with second quarter revenue from operations growing 12% year-on-year and a PAT growth of 2%. This result reflects a robust operating performance as we have adapted to the COVID-19 situation. We are at near normal operating levels with all our scientists working on site with proper protective measures.
We are happy to continue to support the global health community in the fight against COVID-19 through our dedicated RT PCR testing laboratory, our research efforts and by developing and supplying reagents and oligonucleotides to diagnostic kit manufacturers.
The credit rating upgrade by ICRA is a further affirmation of Syngene’s strong fundamentals and the confidence the market has in our growth story. We expect to sustain our growth through the second half and are making good progress towards achieving our full year guidance.”
Quarterly Financial Highlights (All numbers in INR Cr except Margins)
| Q2 FY21 | Q2 FY20 | YoY Change (%) | |
| Revenue | 533 | 485 | 10 |
| Revenue from operations | 519 | 465 | 12 |
| EBITDA | 169 | 160 | 6 |
| EBITDA Margin (%) | 32 | 33 | |
| PAT excluding exceptional gain related to insurance claim | 84 | 82 | 2 |
| PAT Margin (%) | 16 | 17 |
H1 FY21 Financial Highlights (All numbers in INR Cr except Margins)
| H1 FY21 | H1 FY20 | YoY Change (%) | |
| Revenue | 970 | 927 | 5 |
| Revenue from operations | 941 | 886 | 6 |
| EBITDA | 309 | 301 | 3 |
| EBITDA Margin (%) | 32 | 32 | |
| PAT excluding exceptional gain related to insurance claim
|
142 | 154 | -8 |
| PAT Margin (%) | 15 | 17 |
Business Update
Syngene’s second quarter performance was primarily driven by good performance in the Discovery Services and Dedicated R&D Centre divisions. After implementing a broad array of COVID-19 protective and control measures, including regular free testing for all employees working on site, operations have returned to near normal operating levels.
The Company commenced manufacturing of Remdesivir at its manufacturing facility in Bengaluru with initial distribution expected during the third quarter.
Syngene continues to make an active contribution to the fight against COVID-19. In addition to processing COVID-19 tests for hospitals in the Bengaluru region, the Company has tied up with more than 50 organisations in and around Bengaluru to conduct RT-PCR tests for their employees. The Company’s IgG based ELISA test kit has received the ICMR and CDSCO approvals and will be launched by HiMedia shortly. This type of kit will be particularly important to measure optimum immune response once vaccine deployment has started. Furthermore, the Company has joined a global industry consortium, led by long-standing research partner, Bristol Myers Squibb, to support research related to COVID-19. The consortium will share relevant expertise and experience to accelerate the understanding of the virus and work towards improving and deploying current assays and new approaches to COVID-19 testing.
In a further boost to the Company’s credit rating, ICRA upgraded its credit rating in August from AA to AA+. This is a further affirmation of Syngene’s strong fundamentals and robust business model.